These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 16340158)
1. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver. Tanimoto A; Kuribayashi S Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis. Tanimoto A; Kreft BP; Baba Y; Zhao L; Finn JP; Compton CC; Stark DD J Magn Reson Imaging; 1993; 3(5):786-93. PubMed ID: 8400566 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of superparamagnetic iron oxide for MR imaging of liver injury: proton relaxation mechanisms and optimal MR imaging parameters. Tanimoto A; Mukai M; Kuribayashi S Magn Reson Med Sci; 2006 Jul; 5(2):89-98. PubMed ID: 17008765 [TBL] [Abstract][Full Text] [Related]
4. Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging. Choi JY; Kim MJ; Kim JH; Kim SH; Ko HK; Lim JS; Oh YT; Chung JJ; Yoo HS; Lee JT; Kim KW Eur J Radiol; 2006 Oct; 60(1):84-90. PubMed ID: 16920315 [TBL] [Abstract][Full Text] [Related]
5. The value of fast and ultrafast T2-weighted MR imaging sequences in hepatic enhancement with ferumoxides: comparison with conventional spin-echo sequence. Abe Y; Yamashita Y; Namimoto T; Tang Y; Takahashi M Radiat Med; 2000; 18(2):97-105. PubMed ID: 10888042 [TBL] [Abstract][Full Text] [Related]
6. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224 [TBL] [Abstract][Full Text] [Related]
7. Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity. Tanabe M; Ito K; Shimizu A; Fujita T; Onoda H; Yamatogi S; Washida Y; Matsunaga N Magn Reson Imaging; 2009 Jul; 27(6):801-6. PubMed ID: 19144487 [TBL] [Abstract][Full Text] [Related]
10. Contrast-enhanced MR imaging of the liver. Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423 [TBL] [Abstract][Full Text] [Related]
11. Development of hepatomas in hyperplastic nodules induced in the rat liver: detection with superparamagnetic iron oxide-enhanced magnetic resonance imaging. Yamamoto H; Yamashita Y; Takahashi M Acad Radiol; 1996 Apr; 3(4):330-5. PubMed ID: 8796683 [TBL] [Abstract][Full Text] [Related]
12. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents. Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202 [TBL] [Abstract][Full Text] [Related]
13. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Wang C Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis of fatty liver with MR imaging. Kreft BP; Tanimoto A; Baba Y; Zhao L; Chen J; Middleton MS; Compton CC; Finn JP; Stark DD J Magn Reson Imaging; 1992; 2(4):463-71. PubMed ID: 1633400 [TBL] [Abstract][Full Text] [Related]
15. Effect of superparamagnetic iron oxide on tumor-to-liver contrast at T2*-weighted gradient-echo MRI: comparison between 3.0T and 1.5T MR systems. Kim T; Murakami T; Hori M; Onishi H; Tomoda K; Nakamura H J Magn Reson Imaging; 2009 Mar; 29(3):595-600. PubMed ID: 19243054 [TBL] [Abstract][Full Text] [Related]
16. Time-to-echo optimization for spin echo magnetic resonance imaging of liver metastasis using superparamagnetic iron oxide particles. Alger JR; Harreld JH; Chen S; Mintorovitch J; Lu DS J Magn Reson Imaging; 2001 Nov; 14(5):586-94. PubMed ID: 11747011 [TBL] [Abstract][Full Text] [Related]
17. [Magnetic resonance imaging of the liver: what kind of contrast agents?]. De Gaspari A; De Cobelli F; Del Maschio A Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451 [TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Kim YK; Kwak HS; Kim CS; Chung GH; Han YM; Lee JM Radiology; 2006 Feb; 238(2):531-41. PubMed ID: 16371577 [TBL] [Abstract][Full Text] [Related]
20. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla. Park HS; Lee JM; Kim SH; Chang S; Kim SJ; Han JK; Choi BI J Magn Reson Imaging; 2009 Feb; 29(2):328-35. PubMed ID: 19161184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]